Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04422912 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
A Phase 1 study of Pemphigus Vulgaris, sponsored by Cabaletta Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 13
- Study locations
NCT04422912 is a Phase 1 study of Pemphigus Vulgaris that is actively recruiting participants, run by Cabaletta Bio. The registered enrollment target is 40 participants. The trial reports 13 study locations across 10 states.
The verdict
NCT04422912, a Phase 1 study of Pemphigus Vulgaris, is actively recruiting participants, sponsored by Cabaletta Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 13
- Study locations
Study Summary
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Conditions Studied
Interventions
- BIOLOGICAL CABA-201
- BIOLOGICAL DSG3-CAART
Study Locations (13)
California
- Stanford University, Dept. of Dermatology - Redwood City
- UC Davis, Dept. of Dermatology - Sacramento
New York
- Mount Sinai - Icahn School of Medicine - New York
- Columbia University - New York
Texas
- UT Southwestern Medical Center, Dept. of Dermatology - Dallas
- MD Anderson Texas Medical Center - Houston
Connecticut
- Yale University - New Haven
Illinois
- Northwestern University - Chicago
Iowa
- University of Iowa - Iowa City
Massachusetts
- Brigham and Women's Hospital - Boston
North Carolina
- University of North Carolina, Department of Dermatology - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04422912
The ClinicalTrials.gov registry entry for NCT04422912 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cabaletta Bio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pemphigus Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which CABA-201 is the first listed.
NCT04422912 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT04422912 about?
NCT04422912 is a clinical study titled "A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)". A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
What is the current status of trial NCT04422912?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-09-29. Estimated completion is 2029-01.
What conditions does trial NCT04422912 study?
This clinical trial studies the following conditions: Pemphigus Vulgaris.
What interventions are being tested in trial NCT04422912?
The interventions under investigation include: CABA-201 (BIOLOGICAL), DSG3-CAART (BIOLOGICAL).
Who is sponsoring clinical trial NCT04422912?
This trial is sponsored by Cabaletta Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04422912 being conducted?
This trial has 13 study locations across California, Connecticut, Illinois, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pemphigus Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.